title: Reply to PM Brannon et al.
authors.affiliation: Department of Medical Oncology Dana-Farber Cancer Institute 450 Brookline Avenue Boston, MA 02215 E-mail: kimmie_ng@dfci.harvard.edu.
authors.forename: Kimmie
authors.initials: K
authors.lastname: Ng
authors.affiliation: Division of Pediatrics Medical University of South Carolina Charleston, SC.
authors.forename: Bruce W
authors.initials: BW
authors.lastname: Hollis
authors.affiliation: Department of Nutrition Harvard School of Public Health Boston, MA.
authors.forename: Edward L
authors.initials: EL
authors.lastname: Giovannucci
authors.affiliation: Department of Medical Oncology Dana-Farber Cancer Institute Boston, MA.
authors.forename: Charles S
authors.initials: CS
authors.lastname: Fuchs
mesh_terms: D002112:Calcifediol / Q000097:blood*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002762:Cholecalciferol / Q000627:therapeutic use*; D019587:Dietary Supplements; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000517:prevention & control*; D014808:Vitamin D Deficiency / Q000178:diet therapy*
chemical_list: D002762:Cholecalciferol; D002112:Calcifediol